This requires further research to determine the optimal doses of both canagliflozin and radiation, but there is the prospect of using SGLT-2 inhibitors in combination with radiotherapy and, with this type of technology, to treat solid hypoxic tumours, which often develop resistance to chemo- and radiotherapy. The gene discussed is SLC5A2; the disease is neoplasm.